Savara Inc (MSTX)
Savara is a biopharmaceutical company developing clinical-stage therapies for serious or life-threatening diseases. Co.'s key product candidate, AIR001, a sodium nitrite solution for inhalation via nebulization, is in Phase 2 clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure or heart failure with preserved systolic function. Co.'s other product candidate, Vepoloxamer, is a purified poloxamer 188, a nonionic, block copolymer comprised of a central linear chain of hydrophobic polyoxypropylene flanked on both sides by linear hydrophilic polyoxyethylene chains.
|
April 26, 2024 5:01 AM Eastern
Hold (2.00 out of 4)
100th percentile
|
|